- Home
- IBG vs JAGX Comparison
IBG vs JAGX Comparison
Compare IBG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- JAGX
- Stock Information
- Founded
- IBG 2018
- JAGX 2013
- Country
- IBG Australia
- JAGX United States
- Employees
- IBG N/A
- JAGX N/A
- Industry
- IBG Beverages (Production/Distribution)
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- JAGX Health Care
- Exchange
- IBG Nasdaq
- JAGX Nasdaq
- Market Cap
- IBG 5.4M
- JAGX 3.9M
- IPO Year
- IBG 2024
- JAGX N/A
- Fundamental
- Price
- IBG $0.33
- JAGX $1.86
- Analyst Decision
- IBG Strong Buy
- JAGX Strong Buy
- Analyst Count
- IBG 1
- JAGX 1
- Target Price
- IBG N/A
- JAGX $60.00
- AVG Volume (30 Days)
- IBG 595.4K
- JAGX 136.2K
- Earning Date
- IBG 11-15-2025
- JAGX 11-12-2025
- Dividend Yield
- IBG N/A
- JAGX N/A
- EPS Growth
- IBG N/A
- JAGX N/A
- EPS
- IBG N/A
- JAGX N/A
- Revenue
- IBG $2,931,243.00
- JAGX $11,810,000.00
- Revenue This Year
- IBG N/A
- JAGX $22.41
- Revenue Next Year
- IBG N/A
- JAGX $30.00
- P/E Ratio
- IBG N/A
- JAGX N/A
- Revenue Growth
- IBG N/A
- JAGX 15.96
- 52 Week Low
- IBG $0.30
- JAGX $1.57
- 52 Week High
- IBG $3.35
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- IBG 31.14
- JAGX 44.33
- Support Level
- IBG $0.30
- JAGX $1.88
- Resistance Level
- IBG $0.48
- JAGX $2.16
- Average True Range (ATR)
- IBG 0.07
- JAGX 0.12
- MACD
- IBG -0.01
- JAGX 0.04
- Stochastic Oscillator
- IBG 10.59
- JAGX 49.15
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.